Myriad Genetics, Inc. (NASDAQ:MYGN) EVP Paul Parkinson sold 11,824 shares of Myriad Genetics stock in a transaction dated Friday, January 8th. The stock was sold at an average price of $25.00, for a total value of $295,600.00. Following the completion of the transaction, the executive vice president now owns 76,746 shares of the company’s stock, valued at $1,918,650. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Shares of MYGN stock opened at $24.82 on Thursday. The firm has a market capitalization of $1.87 billion, a PE ratio of -9.55 and a beta of 1.69. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.75 and a current ratio of 2.95. Myriad Genetics, Inc. has a 1 year low of $9.24 and a 1 year high of $30.13. The stock has a fifty day moving average of $19.65 and a two-hundred day moving average of $14.85.

Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.15. The business had revenue of $145.20 million for the quarter, compared to analysts’ expectations of $134.59 million. Myriad Genetics had a negative net margin of 32.49% and a negative return on equity of 4.07%. The company’s revenue was down 22.1% on a year-over-year basis. During the same period in the previous year, the business earned $0.08 earnings per share. Equities research analysts predict that Myriad Genetics, Inc. will post -0.57 earnings per share for the current fiscal year.

MYGN has been the topic of a number of research analyst reports. Piper Sandler increased their target price on Myriad Genetics from $14.00 to $18.00 and gave the stock a “neutral” rating in a report on Tuesday, November 10th. BidaskClub raised Myriad Genetics from a “hold” rating to a “buy” rating in a report on Friday, December 25th. Finally, ValuEngine lowered Myriad Genetics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 5th. Three equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $13.60.

Large investors have recently modified their holdings of the company. California State Teachers Retirement System grew its position in shares of Myriad Genetics by 1.3% in the second quarter. California State Teachers Retirement System now owns 108,819 shares of the company’s stock valued at $1,234,000 after purchasing an additional 1,405 shares during the last quarter. American International Group Inc. increased its stake in shares of Myriad Genetics by 2.9% in the second quarter. American International Group Inc. now owns 50,673 shares of the company’s stock valued at $575,000 after buying an additional 1,442 shares in the last quarter. Swiss National Bank raised its holdings in shares of Myriad Genetics by 1.6% in the third quarter. Swiss National Bank now owns 169,000 shares of the company’s stock valued at $2,204,000 after buying an additional 2,600 shares during the last quarter. Envestnet Asset Management Inc. lifted its position in Myriad Genetics by 3.5% during the 3rd quarter. Envestnet Asset Management Inc. now owns 81,293 shares of the company’s stock worth $1,060,000 after buying an additional 2,718 shares in the last quarter. Finally, Stifel Financial Corp grew its holdings in Myriad Genetics by 14.7% during the 2nd quarter. Stifel Financial Corp now owns 26,747 shares of the company’s stock worth $303,000 after acquiring an additional 3,424 shares during the last quarter. 91.06% of the stock is owned by institutional investors.

About Myriad Genetics

Myriad Genetics, Inc, a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool.

Featured Story: What is meant by a buy rating?

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.